Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and apatinib in advanced acral melanoma
NCT03955354Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2019
- Primary completion
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in acral lentiginous melanoma (ALM), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT03955354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955354.